Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of signed and dated informed consent before initiation of any study-related procedures
Male or female patients aged 18 years or older
Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment
Females must be post menopausal or surgically sterile Self-identified as African American
You may not be if
Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
Current smokers, including the use of tobacco containing products in the past 1 month of randomization Patients required dialysis
Clareo Health | A Pharmacodynamic Study With Ticagrelor in African American Patients
